We are committed to the principles of good Corporate Governance for a responsible, transparent and long-term increase of the Company's value.

Corporate Governance at APONTIS PHARMA

Team

Management

  • Karlheinz Gast CEO active in the industry since 1986 and holding the following company positions since 1997:
    • General Manager BU Internal Medicine (UCB Pharma GmbH)
    • Senior Director BU Internal Medicine (UCB Pharma GmbH)
    • Sales Director (Schwarz Pharma Deutschland GmbH)

    Curriculum vitae

  • Thomas Milz CPO active in the industry since 1991 and holding the following company positions from 1991 to 1996 and since 1997:
    • Director Market Access (UCB Pharma GmbH)
    • Director Marketing (Schwarz Pharma Deutschland GmbH)
    • Product Manager & Head of Marketing Vascular (Schwarz Pharma Deutschland GmbH)

    Curriculum vitae

Supervisory Board

Share buyback programs

Share buyback program 2022/I


  • 4. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

  • 3. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

  • 2. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

  • 1. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR)

  • APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052


Share buyback program 2022/II


  • 8. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • 7. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • 6. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • 5. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • 4. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • 3. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • 2. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • 1. Interim announcement – APONTIS PHARMA AG Share buyback: Disclosure pursuant to Article 5 paragraph 1 lit. b) and paragraph 3 of the Regulation (EU) No. 596/2014 (MAR) in connection with Article 2 paragraph 2 and paragraph 3 of the Delegated Regulation (EU) No. 2016/1052

  • APONTIS PHARMA AG: Notice according to Article 2 paragraph 1 of Delegated Regulation (EU) 2016/1052

Managers' Transactions

  • There are no current managers’ transactions available.
  • There are no current managers’ transactions available.

Annual General Meeting

Documents


  • Declaration of Compliance 2021 (German only)

  • Code of Conduct of the APONTIS PHARMA Group (German only)

  • Articles of Association of APONTIS PHARMA AG (German only)

  • Bylaws for the Supervisory Board of APONTIS PHARMA AG (German only)

CONTACT INVESTOR RELATIONS

I look forward to your message

Do not miss any publications or news about APONTIS PHARMA AG. By registering for our IR mailings, you will always stay informed.